Vaccination of the Immunocompromised Host

Publication Date: December 4, 2013

Responsibility for Vaccination

1. Specialists caring for immunocompromised patients share responsibility with the primary care provider for ensuring that appropriate vaccinations are administered to immunocompromised patients.* (SR, L)
21881
2. Specialists caring for immunocompromised patients share responsibility with the primary care provider for recommending appropriate vaccinations for household members of immunocompromised patients.* (SR, VL)
21881

Timing of Vaccination

3. Vaccines should be administered prior to planned immunosuppression if feasible. (SR, M)
21881
4. Live vaccines should be administered ≥4 weeks prior to immunosuppression.* (SR, L)
21881
and should be avoided within 2 weeks of initiation of immunosuppression. (SR, L)
21881
5. Inactivated vaccines should be administered ≥2 weeks prior to immunosuppression. (SR, M)
21881

Household Members (See Table 1)

6. Immunocompetent household members of immunocompromised patients can safely receive inactivated vaccines based on the Centers for Disease Control and Prevention (CDC) Advisory Committee on Immunization Practices (ACIP)’s annually updated recommended vaccination schedules for children and adults (hereafter referred to as the CDC annual schedule). (SR, H)
21881
or for travel. (SR, M)
21881
7. Household members of immunocompromised patients 6 months and older should receive influenza vaccine annually. (SR, H)

They should receive either:

21881
a. Inactivated influenza vaccine (IIV) or (SR, H)
21881
b. Live attenuated influenza vaccine (LAIV) provided they are healthy, not pregnant, and age 2-49 years. (SR, L)
21881
Exceptions include household members of an immunocompromised patient who is a hematopoietic stem cell transplant (HSCT) recipient within 2 months after transplant or with graft-vs-host disease (GVHD), or a patient with severe combined immunodeficiency (SCID).* In these exceptions, LAIV should NOT be administered. (WR, VL)
21881

or, if administered, contact between the immunocompromised patient and household member should be avoided for 7 days.

(WR, VL)
21881
8. Healthy immunocompetent household members of immunocompromised patients should receive the following live vaccines based on the CDC annual schedule: combined measles, mumps, and rubella vaccines (MMR), (SR, M)
21881
rotavirus vaccine in infants ages 2-7 months, (SR, L)
21881
varicella vaccine (VAR), (SR, M)
21881
and zoster vaccine (ZOS). (SR, M)
21881
They can safely receive vaccines for travel: yellow fever vaccine, (SR, M)
21881
and oral typhoid vaccine. (SR, L)
21881
9. Oral poliovirus vaccine (OPV) should NOT be administered to household members of immunocompromised patients. (SR, M)
21881
10. Highly immunocompromised patients should avoid handling diapers of infants vaccinated with rotavirus vaccine for 4 weeks after vaccination. (SR, VL)
21881
11. Immunocompromised patients should avoid contact with persons who develop skin lesions after receiving VAR or ZOS until the lesions have cleared. (SR, L)
21881

Table 1. Safety of Administration of Live Vaccines to Contacts of Immunocompromised Persons

Influenza, live, attenuated nasal

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Yes (nasal secretions) Rare (from 1 vaccinated toddler)
Administer; (SR, L)
21881
vaccinated persons to avoid close contact with persons with HSCT or SCID for 7 d. (WR, VL)
21881

MMR

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Measles: no
Mumps: no
Rubella: yes
(nasopharynx, in low titer; breast milk)		 No, except mother-to-infant transmission of rubella vaccine virus via breast milk
Administer (SR, M)
21881

Poliovirus, oral

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Yes (stool) Yes, with rare cases of vaccine-associated paralytic poliomyelitis
Do NOT administer (SR, H)
21881

Rotavirus, oral

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Yes (stool) Yes, but no reported cases of symptomatic infection in contacts
Administer (SR, L)
21881

Typhoid, oral

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
No No
Administer (SR, L)
21881

Varicella

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Yes (skin lesions) Rare, limited to vaccinees with skin lesions
Administer (SR, M)
If skin lesions develop, avoid close contact with immunocompromised persons.
21881

Yellow fever

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
No, except possibly shed in breast milk Yes (at least 3 cases of encephalitis in infants exposed to the vaccine via nursing)
Administer (SR, M)
except to women who are nursing.
21881

Zoster

Shedding of Agent? (Site) Transmissibility From Vaccinated Immunocompetent Person?
Yes (rarely recovered from injection-site vesicles) Not reported
Administer to age ≥60 y. (SR, M)
If skin lesions develop, avoid close contact with immunocompromised persons.
21881

International Travel

12. Clinicians may administer inactivated vaccines indicated for travel based on the CDC annual schedule for immunocompetent adults and children. (SR, L)
21881

13. Yellow fever vaccine generally should NOT be administered to immunocompromised persons.

(SR, M)
21881

If travel to an endemic area cannot be avoided, vaccination can be considered in certain adults with human immunodeficiency virus (HIV) infection who are minimally immunocompromised:

a. Asymptomatic HIV-infected adults with CD4 T-cell lymphocyte counts of ≥200 cells/mm3.

(WR, L)
21881

b. Asymptomatic HIV-infected children age 9 months through 5 years with CD4 T-cell lymphocyte percentages of ≥15%.

(, )
21881
14. With certain exceptions (eg, yellow fever vaccine and MMR-infected patients [see recommendation 13 and HIV section] and MMR in certain HSCT patients [see HSCT section]), live vaccines should NOT be given to immunocompromised persons. (SR, L)
21881

Specific Vaccinations

Varicella and Zoster Vaccines

VAR should be given to immunocompetent patients without evidence of varicella immunity (ie, either age-appropriate varicella vaccination, serologic evidence of immunity, clinician-diagnosed or verified history of varicella or zoster, or laboratory-proven varicella or zoster). (SR, M)
21881
if it can be administered ≥4 weeks before initiating immunosuppressive therapy. (SR, L)
21881
16. A 2-dose schedule of VAR, separated by >4 weeks for patients ≥13 years and by ≥3 months for patients 1-12 years of age, is recommended if there is sufficient time prior to initiating immunosuppressive therapy. (SR, L)
21881
17. VAR should NOT be administered to highly immunocompromised patients, but certain categories of patients (eg, patients with HIV infection without severe immunosuppression, or a primary immunodeficiency disorder without defective T cell-mediated immunity, such as primary complement component deficiency disorder, or chronic granulomatous disease [CGD]) should receive VAR, adhering to a 2-dose schedule separated by a 3-month interval. (SR, M)
21881
18. VAR can be considered for patients without evidence of varicella immunity (defined in recommendation 16) who are receiving long-term, low-level immunosuppression.* (WR, VL)
21881
19. VAR should be administered to eligible immunocompromised patients as the single antigen product, not varicella vaccine combined with measles, mumps, and rubella vaccines (MMRV). (SR, L)
21881
20. ZOS should be given to patients ≥60 years of age if it can be administered ≥4 weeks before beginning highly immunosuppressive therapy. (SR, L)
21881
21. ZOS should be considered for varicella-positive patients (ie, persons with a history of varicella or zoster infection or who are VZV seropositive with no previous doses of VAR) 50-59 years of age if it can be administered ≥4 weeks before beginning immunosuppressive therapy.* (WR, L)
21881
22. ZOS should be administered to patients ≥60 years of age receiving therapy considered to induce a low level of immunosuppression. (SR, L)
21881
23. ZOS should NOT be administered to highly immunocompromised patients. (SR, VL)
21881

Influenza

24. Annual influenza vaccination with IIV is recommended for immunocompromised patients ≥6 months of age. (SR, M)
21881
except for patients who are very unlikely to respond (although unlikely to be harmed by IIV), such as those receiving intensive chemotherapy.* (SR, L)
21881
or those who have received anti-B cell antibodies within 6 months.* (SR, M)
21881
25. LAIV should NOT be administered to immunocompromised persons. (WR, VL)
21881

Special Populations

Primary (Congenital) Immunodeficiency Disorders

Primary Complement Deficiencies

26. Patients with primary complement deficiencies should receive all routine vaccines based on the CDC annual schedule. None is contraindicated. (SR, L)
21881
27. Patients with primary complement deficiencies and who are:
a. 2-5 years old should receive 1 dose of 13-valent pneumococcal conjugate vaccine (PCV13) if they have received 3 doses of pneumococcal conjugate vaccine (PCV) (either 7-valent pneumococcal conjugate vaccine [PCV7] or PCV13) before 24 months of age, and 2 doses of PCV13 (8 weeks apart) if they have received an incomplete schedule of ≤2 doses of PCV (PCV7 or PCV13) before 24 months of age. (SR, L)
21881
b. 6-18 years old with a classical pathway (C1, C2, C3, C4), alternate pathway, or severe mannan-binding lectin (MBL) deficiency who have not received PCV13 should receive a single dose of PCV13. (SR, VL)
21881
c. ≥19 years old with a classical pathway (C1, C2, C3, C4), alternate pathway, or severe MBL-naive should receive a single dose of PCV13. (SR, VL)
21881
For those who have previously received 23-valent pneumococcal polysaccharide vaccine (PPSV23), PCV13 should be administered ≥1 year after the last PPSV23 dose. (WR, L)
21881
28. Patients ≥2 years of age with an early classical pathway, alternate pathway, or severe MBL deficiency should receive PPSV23 ≥8 weeks after PCV13 and a second dose of PPSV23 5 years later. (SR, L)
21881
29. Patients with primary complement deficiencies should receive conjugate meningococcal vaccine.
For children age 6 weeks through 18 months, administer a 4-dose series of bivalent meningococcal conjugate vaccine and H. influenzae type b conjugate vaccine (Hib-MenCY; MenHibrix®) at 2, 4, 6, and 12-15 months. (SR, L)
21881
or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4or a 2-dose primary series of quadrivalent meningococcal conjugate vaccine (MCV4) to patients with primary complement component deficiency age 9 months through 55 years (MCV4-D [Menactra®] for those 9-23 months; MCV4-D or MCV4-CRM [Menveo®] for those 2-54 years of age). (SR, L)
21881
For persons >55 years of age, administer MPSV4 if they have not previously received MCV4 and MCV4 if they have previously received it. (SR, L)
21881
For patients 9-23 months of age, administer the doses 3 months apart, and for patients 2 years and older, administer the doses 2 months apart. MCV4-D should be administered ≥4 weeks after a dose of PCV13 because of a reduced antibody response to some pneumococcal serotypes when MCV4-D and PCV7 are administered simultaneously. (SR, L)
21881
30. Patients with a primary complement component deficiency should be revaccinated with MCV4 (or MPSV4 for those >55 years of age who have not previously received MCV4) every 5 years. (SR, L)
21881

Phagocytic Cell Deficiencies

Phagocytic cell deficiencies include CGD (chronic granulomatous disease), leukocyte adhesion deficiency, and Chediak-Higashi syndrome.
31. Patients with phagocytic cell deficiencies should receive all inactivated vaccines based on the CDC annual schedule. (SR, L)
21881
Children 2-5 years of age should receive PCV13 as in recommendation 27a. (WR, VL)
21881
32. Patients ≥6 years of age with phagocytic cell deficiencies other than CGD (unless patient with CGD is receiving immunosuppressive medication) should receive PCV13 as in recommendations 27b-c. (WR, VL)
21881
33. Patients ≥2 years of age with phagocytic cell deficiencies other than CGD (unless patient with CGD is receiving immunosuppressive medication) should receive PPSV23 ≥8 weeks after PCV13 and a second dose of PPSV23 5 years later. (WR, L)
21881
34. Live bacterial vaccines, such as bacillus Calmette-Guérin (BCG) or oral typhoid vaccine, should NOT be administered to patients with a phagocytic cell defect. (SR, M)
21881
35. Live viral vaccines should be administered to patients with CGD and to those with congenital or cyclical neutropenia. (WR, L)
21881
36. Live viral vaccines should NOT be administered to patients with leukocyte adhesion deficiency, defects of cytotoxic granule release such as Chediak-Higashi syndrome (see Combined Immunodeficiencies), or any other undefined phagocytic cell defect. (SR, L)
21881

Innate Cytokine or Cellular Activation Defects

Innate defects in the immune system resulting in defects of cytokine generation, cytokine response, or cellular activation include defects
of the interferon-γ/interleukin 12 axis.
37. Patients with innate immune system defects resulting in defects of cytokine generation/response or cellular activation should receive all inactivated vaccines based on the CDC annual schedule. (SR, VL)
21881
38. For patients with innate immune system defects resulting in defects of cytokine generation/response or cellular activation, PCV13 should be administered as in recommendations 27a-c. (, )
(WR to SR-VL to L)
21881
39. Specialist advice should be sought on individual conditions concerning use of live vaccines in patients with innate immune system defects resulting in defects of cytokine generation/response or cellular activation/inflammation generation. (SR, L)
21881
40. Live bacterial vaccines should NOT be administered to patients with defects of the interferon- γ/interleukin 12 pathways. (SR, M)
21881
41. Live viral vaccines should NOT be administered to patients with defects of interferon ( α or γ) production. (SR, L)
21881

Minor Antibody Deficiencies

42. Patients with immunoglobulin A (IgA) deficiency or specific polysaccharide antibody deficiency (SPAD) should receive all routine vaccinations based on the CDC annual schedule, provided that other components of their immune system are normal. (SR, L)
21881
43. Children with SPAD or ataxia-telangiectasia should receive PCV13 as described in recommendations 27a-c. (, )

(WR to SR-VL to L)

21881
Those ≥2 years of age should receive PPSV23 ≥8 weeks after indicated doses of PCV13 and a second dose of PPSV23 5 years later. (SR, L)
21881
44. Monitoring of vaccine responses can be useful for assessing the degree of immunodeficiency in patients with minor antibody deficiencies and the level of protection. (WR, M)
21881
45. OPV should NOT be administered to IgA-deficient patients. (SR, L)
21881

Major Antibody Deficiencies in Patients Receiving Immunoglobulin Therapy

46. Inactivated vaccines other than IIV are NOT routinely administered to patients with major antibody deficiencies during immunoglobulin therapy. (SR, L)
21881
For patients with suspected major antibody deficiencies, all inactivated vaccines can be administered as part of assessing the immune response prior to immunoglobulin therapy. (SR, L)
21881
47. IIV can be administered to patients with major antibody deficiencies and some residual antibody production. (WR, L)
21881
48. Live OPV should NOT be administered to patients with major antibody deficiencies. (SR, M)
21881
49. Live vaccines (other than OPV) should NOT be administered to patients with major antibody deficiencies.* (WR, L)
21881

Combined Immunodeficiencies

50. For patients with suspected combined immunodeficiencies, all inactivated vaccines can be administered as part of assessing the immune response prior to commencement of immunoglobulin therapy. (SR, L)
21881
For patients with combined immunodeficiencies who are receiving immunoglobulin therapy, inactivated vaccines should NOT be routinely administered. (SR, L)
21881
51. For patients with combined immunodeficiencies and residual antibody production potential, IIV can be administered. (WR, VL)
21881
52. Children with partial DiGeorge syndrome (pDGS) should undergo immune system assessment with evaluation of lymphocyte subsets and mitogen responsiveness to decide whether they should be given live viral vaccines. Those with ≥500 CD3 T-cells/mm3, ≥200 CD8 T-cells/mm3, and normal mitogen response should receive MMR and VAR.* (WR, L)
21881
53. Patients with SCID, DiGeorge syndrome with CD3 T-cell lymphocyte count of <500 cells/mm3, other combined immunodeficiencies with similar CD3 T-cell lymphocyte counts, Wiskott-Aldrich syndrome, or X-linked lymphoproliferative disease and familial disorders predisposing to hemophagocytic lymphohistiocytosis, should avoid all live vaccines. (SR, M)
21881

HIV-Infected Adults, Adolescents, and Children (See Table 2)

Inactivated Vaccines

54. HIV-infected patients should be vaccinated according to the CDC annual schedule for the following inactivated vaccines:
IIV, (SR, H)
21881
PCV13 in patients <2 years. (SR, M)
21881
H. influenzae type b conjugate vaccine (Hib), (SR, H)
21881
diphtheria toxoid, tetanus toxoid, acellular pertussis vaccine (DTaP), (SR, M)
21881
tetanus toxoid, reduced diphtheria toxoid, and reduced acellular pertussis vaccine (Tdap), (SR, VL)
21881
tetanus toxoid, reduced diphtheria toxoid vaccine (Td), (SR, L)
21881
hepatitis B vaccine (HepB), (SR, M)
21881
hepatitis A vaccine (HepA), (SR, M)
21881
inactivated poliovirus vaccine (IPV), (SR, M)
21881
and quadrivalent human papillomavirus vaccine (HPV4)* in females and males 11-26 years of age. (SR, VL)
21881
with additions noted below.
55. PCV13 should be administered to HIV-infected patients ≥2 years old as in recommendations 27a-c. (See Table 2) (SR, )
(SR-L to M)
21881
56. PPSV23 should be administered to HIV-infected children ≥2 years of age who have received indicated doses of PCV. (SR, M)
21881
to HIV-infected adults with CD4 T-lymphocyte counts of ≥200 cells/mm3, (SR, M)
21881
and to HIV-infected adults with CD4 T-lymphocyte counts of <200 cells/mm3, (WR, L)
21881
PPSV23 should be given ≥8 weeks after the indicated dose(s) of PCV13 and a second dose of PPSV23 should be given 5 years later. (SR, L)
21881
57. HIV-infected children who are >59 months of age and have not previously received Hib should receive 1 dose of Hib. (SR, L)
21881
Hib is NOT recommended for HIV-infected adults. (WR, L)
21881
58. HIV-infected children age 11-18 years should receive a 2-dose primary series of MCV4 two months apart. (SR, M)
21881
A single booster dose (third dose) should be given at age 16 years if the primary series was given at age 11 or 12 years, and at age 16-18 years if the primary series was given at age 13-15 years. (SR, L)
21881
If MCV4 is administered to HIV-infected children 2-10 years of age because of risk factors for meningococcal disease, a 2-dose primary series of MCV4 should be administered with a 2-month interval between doses and a booster dose 5 years later. (SR, VL)
21881
59. HIV-infected patients should receive HepB series, (SR, M)
21881
with consideration of high-dose HepB (40 μg/dose) for adults (WR, M)
21881
and adolescents.* (WR, L)
21881
One to two months after completion, they should be tested for anti-HBs (antibodies to hepatitis B surface antigen). (SR, L)
21881
If a postvaccination anti-HBs concentration of ≥10 mIU/mL is not attained, a second 3-dose series of HepB (SR, L)
21881
should be administered (alternative: 1 dose of HepB after which anti-HBs is tested*) using standard-dose (SR, M)
21881
or high-dose HepB (40 μg/dose)* (WR, L)
21881
for children and high-dose HepB for adolescents* and adults. (SR, L)
21881
60. HepB containing 20 μg of HBsAg (hepatitis B surface antigen) combined with HepAHepB containing 20 μg of HBsAg (hepatitis B surface antigen) combined with HepAHepB containing 20 μg of HBsAg (hepatitis B surface antigen) combined with HepAHepB containing 20 μg of HBsAg (hepatitis B surface antigen) combined with HepA (HepA-HepB; Twinrix®) 3-dose series can be used for primary vaccination of HIV-infected patients ≥12 years of age.* (SR, M)
21881
61. Internationally adopted HIV-infected children who had prior doses of OPV should receive a total of 4 doses of a combination of OPV and IPV vaccines. (SR, L)
21881
62. HPV4 is recommended over bivalent human papillomavirus vaccine (HPV2) because HPV4 prevents genital warts,* (SR, L)
although there are no data on differences between the vaccines for preventing cervical dysplasia in HIV-infected women.
21881

Live Vaccines

63. HIV-exposed or -infected infants should receive rotavirus vaccine according to the schedule for uninfected infants. (SR, L)
21881
64. HIV-infected patients should NOT receive LAIV. (WR, VL)
21881
65. MMR should be administered to clinically stable HIV-infected children 1-13 years old without severe immunosuppression (SR, M)
21881
and HIV-infected patients ≥14 years without measles immunity and with a CD4 T-cell lymphocyte count of ≥200/mm3. (WR, VL)
21881
66. HIV-infected children with a CD4 T-cell percentage of <15% (SR, M)
21881
or patients ≥14 years with a CD4 T-cell lymphocyte count of <200 cells/mm3 should NOT receive MMR. (SR, M)
21881
67. HIV-infected patients should NOT receive quadrivalent MMR-varicella vaccine (MMRV). (SR, VL)
21881
68. Varicella-nonimmune, clinically stable HIV-infected patients age 1-8 years with ≥15% CD4 T-lymphocyte percentage, (SR, H)
21881
age 9-13 years with ≥15% CD4 T-lymphocyte percentage, (SR, VL)
21881
and age ≥14 years with CD4 T-lymphocyte counts of ≥200 cells/mm3, (SR, VL)
21881
The 2 doses should be separated by ≥3 months. (SR, M)
21881
should receive VAR.

Table 2. Vaccination of Persons With HIV Infection

H. influenzae type b conjugate

Low-Levela or No Immunosuppression
U: age <5 y (SR, H)
21881
R: age 5–18 yc (SR, L)
21881
High-Level Immunosuppressionb
U: age <5 y (SR, H)
21881
R: age 5–18 yc (SR, L)
21881

Hepatitis A

Low-Levela or No Immunosuppression
U: (SR, M)
21881
High-Level Immunosuppressionb
U: age 1 y (SR, M)
21881

Hepatitis Bd

Low-Levela or No Immunosuppression
R: (SR, M)
21881
High-Level Immunosuppressionb
R: (SR, M)
21881

DTaP

Low-Levela or No Immunosuppression
U: (SR, M)
21881
High-Level Immunosuppressionb
U: (SR, M)
21881

Tdap

Low-Levela or No Immunosuppression
U: (SR, VL)
21881
High-Level Immunosuppressionb
U: (SR, VL)
21881

Td

Low-Levela or No Immunosuppression
U: (SR, L)
21881
High-Level Immunosuppressionb
U: (SR, L)
21881

HPV4e

Low-Levela or No Immunosuppression
U: age 11-26 y (SR, VL)
21881
High-Level Immunosuppressionb
U: age 11-26 y (SR, VL)
21881

Influenza, inactivated

Low-Levela or No Immunosuppression
U: (SR, H)
21881
High-Level Immunosuppressionb
U: (SR, H)
21881

Influenza, live attenuated

Low-Levela or No Immunosuppression
X:f (WR, VL)
21881
High-Level Immunosuppressionb
X: (WR, VL)
21881

MMR, live

Low-Levela or No Immunosuppression
U: age 12 mo to 13 y (SR, M)
21881
U: age ≥14 y (WR, VL)
21881
High-Level Immunosuppressionb
X: age 12 mo to 13 y (SR, M)
21881
X: age ≥14 y (SR, M)
21881

MMRV, live

Low-Levela or No Immunosuppression
X: (SR, VL)
21881
High-Level Immunosuppressionb
X: (SR, VL)
21881

Meningococcal conjugateg

Low-Levela or No Immunosuppression
U: age 11-18 y (SR, M)
21881
High-Level Immunosuppressionb
U: age 11-18 y (SR, M)
21881

Pneumococcal conjugate (PCV13)

Low-Levela or No Immunosuppression
U: age <5 y (SR, M)
21881
R: age 5 yh (SR, M)
21881
R: age 6-18 yh (SR, L)
21881
R: age ≥19 yi (SR, L)
21881
High-Level Immunosuppressionb
U: age <5 y (SR, M)
21881
R: age 5 y (SR, M)
21881
R: age 6-18 y (SR, L)
21881
R: age ≥19 yi (SR, VL)
21881

Pneumococcal polysaccharide (PPSV23)j

Low-Levela or No Immunosuppression
R: age ≥2 y (SR, M)
21881
High-Level Immunosuppressionb
R: age 2-18 y (SR, M)
21881
R: adult (CD4 T-lymphocytes <200 cells/mm3) (WR, L)
21881

Poliovirus, inactivated

Low-Levela or No Immunosuppression
U: (SR, M)
21881
High-Level Immunosuppressionb
U: (SR, M)
21881

Rotavirus, live

Low-Levela or No Immunosuppression
U: (SR, L)
21881
High-Level Immunosuppressionb
U: (WR, VL)
21881

Varicella, live

Low-Levela or No Immunosuppression
U: age 1-8 y (SR, H)
21881
U: age ≥9 y (SR, VL)
21881
High-Level Immunosuppressionb
X: (SR, M)
21881

Zoster, live

Low-Levela or No Immunosuppression
X: age <60 y (SR, L)
21881
U: age ≥60 yk, l (WR, L)
21881
High-Level Immunosuppressionb
X: (SR, M)
21881
R, recommended—administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection
U, usual—administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories
X, contraindicated.

a Asymptomatic HIV infection with CD4 T-lymphocyte counts of 200-499 cells/mm3 for adults and adolescents and percentage of 15%-24% for infants and children.
b CD4 T-lymphocyte count of <200 cells/mm3 for adults and adolescents and percentage of <15% for infants and children.
c 1 dose.
d High-dose HepB (40 µg) should be considered for adults (WR, M)
21881
and adolescents (WR, L)
21881
with HIV infection. The latter recommendation deviates from CDC ACIP recommendations.
eHPV4 is preferred over HPV2 because of its activity against genital warts, a recommendation for administration of a vaccine that deviates from CDC ACIP recommendations.
fLAIV-infected patients age 5-17 years on a highly active antiretroviral therapy (HAART) regimen for ≥16 weeks with CD4 T-lymphocyte percentage of ≥15% and HIV plasma RNA of <60,000 copies.
g For HIV-infected patients, MCV4 is administered as a 2-dose primary series separated by ≥2 months. A booster dose (third dose) should be administered at age 16 years if the initial series was given at age 11-12 years and at age 16-18 years if the initial series was given at age 13-15 years.
h For patients not fully vaccinated with PCV13 by previous administration.
i For patients ≥19 years of age with HIV who have previously received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose. (WR, L)
21881
j PPSV23 should be administered 8 weeks or longer after indicated dose(s) of PCV13. A second dose of PPSV23 should be administered 5 years after the initial dose.
k Vaccination can be considered for patients 50 through 59 years of age not previously vaccinated with varicella vaccine, (WR, L)
a recommendation for administration of a vaccine that deviates from recommendations of the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.
21881
l For patients not vaccinated with varicella vaccine.

Cancer (See Table 3)

69. Patients ≥6 months of age with hematological malignancies (SR, M)
21881
or solid tumor malignancies (SR, L)
21881
except those receiving anti-B cell antibodies* (SR, M)
21881
or intensive chemotherapy, such as for induction or consolidation chemotherapy for acute leukemia, (WR, L)
21881
should receive IIV annually.*
70. PCV13 should be administered to newly diagnosed adults with hematological (SR, VL)
21881
or solid malignancies (SR, VL)
21881
and children with malignancies (SR, VL)
21881
as described in recommendations 27a-c. (, )
21881

PPSV23 should be administered to adults and children ≥2 years of age

(SR, L)

at least 8 weeks after the indicated dose(s) of PCV13.

21881
71. Inactivated vaccines (other than IIV) recommended for immunocompetent children in the CDC annual schedule can be considered for children who are receiving maintenance chemotherapy. (WR, L)
21881
However, vaccines administered during cancer chemotherapy should NOT be considered valid doses (SR, L)
21881
unless there is documentation of a protective antibody level. (SR, M)
21881
72. Live viral vaccines should NOT be administered during chemotherapy. (SR, VL)
(SR-VL to M)
21881
73. Starting 3 months following cancer chemotherapy, patients should be vaccinated with inactivated vaccines (SR, VL)
(SR-VL to M)
21881
and the live vaccines VAR, (WR, VL)
21881
MMR, (SR, L)
21881
and MMRV (WR, VL)
21881
according to the CDC annual schedule routinely indicated for immunocompetent persons. (, )
21881
If regimens included anti-B cell antibodies, vaccinations should be delayed at least 6 months. (SR, M)
21881

Table 3. Vaccination of Patients With Cancer

H. influenzae type b conjugate

Prior to or During Chemotherapya
U: (WR, L)
21881

Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)

U: (SR, M)
21881

Hepatitis A

Prior to or During Chemotherapya
U: (WR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, VL)
21881

Hepatitis B

Prior to or During Chemotherapya
U: (WR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, M)
21881
R: adults (SR, VL)
21881

DTaP, Tdap

Prior to or During Chemotherapya
U: (WR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: age 0-18 y (SR, M)
21881
R: adults with acute lymphoblastic leukemia or lymphoma (WR, VL)
21881

HPV

Prior to or During Chemotherapya
U: age 11-26 y (WR, VL)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, VL)
21881

Influenza, inactivated

Prior to or During Chemotherapya
U (SR, L)
U (SR-L to M)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U:b (SR, M)
21881

Influenza, live attenuated

Prior to or During Chemotherapya
X: (WR, VL)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, L)
21881

MMR, live

Prior to or During Chemotherapya
X:c (SR, M)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
Starting at 3 mo: U: (SR, L)
21881

MMRV, live

Prior to or During Chemotherapya
X:c (SR, M)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
Starting at 3 mo: U: (WR, VL)
21881

Meningococcal conjugate

Prior to or During Chemotherapya
U (WR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, L)
21881

Pneumococcal conjugate-13 (PCV13)

Prior to or During Chemotherapya
R: (SR, L)
21881
R: age ≥6 yd (SR, VL)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, L)
21881

Pneumococcal polysaccharide (PPSV23)

Prior to or During Chemotherapya
R: age ≥2 y (SR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, L)
21881

Poliovirus, inactivated

Prior to or During Chemotherapya
U: (WR, L)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
U: (SR, L)
21881

Rotavirus, live

Prior to or During Chemotherapya
X: (SR, VL)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
Not applicable (, )
21881

Varicella, live

Prior to or During Chemotherapya
Xc (SR, M)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
Starting at 3 mo: U:e (WR, VL)
21881

Zoster, live

Prior to or During Chemotherapya
X:c (SR, VL)
21881
Starting ≥3 Months Postchemotherapy and ≥6 Months After Anti–B-Cell Antibodies for Inactivated Vaccines (see each live vaccine for interval)
Starting at 3 mo: U:e (WR, VL)
21881
R, recommended—administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection
U, usual—administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories
X, contraindicated.
a Administer inactivated influenza vaccine (IIV) annually to patients with hematological malignancies. (SR, M)
21881
or solid tumor malignancies (SR, L)
21881
except those receiving anti–B-cell antibodies such as rituximab or alemtuzumab or intensive chemotherapy such as for induction or consolidation chemotherapy for acute leukemia. (WR, L)
21881
Administrations of inactivated vaccines other than IIV routinely recommended for healthy children in the annually updated CDC recommendations can be considered for children with malignancies who are receiving maintenance chemotherapy. (WR, L)
21881
However, vaccines administered while receiving cancer chemotherapy should not be considered valid doses. (SR, L)
21881
b IIV can be administered ≤3 months after chemotherapy, but response rate may be low.
c These live vaccines should not be administered unless the vaccine is otherwise indicated based on the annually updated CDC recommendations AND the patient is not immunosuppressed AND there will be an interval of ≥4 weeks prior to initiation of chemotherapy.
d For patients ≥19 years of age with HIV who have previously received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose. (WR, L)
21881
e Although MMR has been given safely 3 months after completion of chemotherapy, data on the safety, immunogenicity, or efficacy of varicella or zoster vaccine after completion of chemotherapy are not available.
f For patients ≥19 years of age who have previously received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose. (WR, L)
21881

Hematopoietic Stem Cell Transplant (See Table 4)

Donors and Patients Before Transplantation

74. The HSCT donor should be current with routinely recommended vaccines based on age, vaccination history, and exposure history according to the CDC annual schedule, (SR, H)
21881
but MMR, MMRV, VAR, and ZOS administration should be avoided within 4 weeks of stem cell harvest. (WR, VL)
21881
Vaccination of the donor for the benefit of the recipient is NOT recommended. (WR, M)
21881
75. Prior to HSCT, candidates should receive vaccines indicated for immunocompetent persons based on age, vaccination history, and exposure history according to the CDC annual schedule if they are not already immunosuppressed. (SR, )
(SR-VL to M)
21881
and when the interval to the start of the conditioning regimen is ≥4 weeks for live vaccines. (SR, L)
21881
and ≥2 weeks for inactivated vaccines. (SR, M)
21881
76. Nonimmune HSCT candidates ≥12 months of age should receive VAR (as a 2-dose regimen if there is sufficient time) if they are not immunosuppressed and when the interval to the start of the conditioning regimen is ≥4 weeks. (SR, L)
21881

HSCT Patients Post-transplantation

77. Administer 1 dose of IIV annually. (SR, M)
21881
to persons ≥6 months of age starting 6 months after HSCT (SR, M)
21881
and starting at 4 months if there is a community outbreak of influenza as defined by the local health department. (SR, VL)
21881
For children 6 months through 8 years of age who are receiving influenza vaccine for the first time, 2 doses should be administered. (SR, L)
21881
78. Administer 3 doses of PCV13 to adults and children starting 3-6 months after HSCT. (, )
21881
At 12 months after HSCT a dose of PPSV23 should be given provided the patient does not have chronic GVHD. (SR, L)
21881
For patients with chronic GVHD a fourth dose of PCV13 can be given at 12 months after HSCT.* (WR, VL)
21881
79. Administer 3 doses of Hib starting at 6-12 months after HSCT. (SR, M)
21881
80. Administer 2 doses of MCV4 starting 6-12 months after HSCT starting 6-12 months after HSCT starting 6-12 months after HSCT starting 6-12 months after HSCT starting 6-12 months after HSCT to persons 11-18 years of age with a booster dose at age 16-18 years for those receiving the initial post-HSCT dose of vaccine at 11-15 years of age. (SR, L)
21881
81. Administer 3 doses of tetanus/diphtheria-containing vaccine starting 6 months after HSCT. (SR, L)
21881
For children <7 years of age, administer 3 doses of DTaP. (SR, L)
21881
For patients 7 years and older, administration of 3 doses of DTaP should be considered.* (WR, VL)
21881
Alternatively, administer a dose of Tdap followed by either 2 doses of diphtheria-tetanus vaccine (DT)* (WR, M)
21881
or 2 doses of Td. (WR, L)
21881
82. Administer 3 doses of HepB starting at 6-12 months after HSCT. (SR, M)
21881
If a postvaccination anti-HBs concentration of ≥10 mIU/mL is not attained, a second 3-dose series of HepB (SR, L)
21881
(Alternative: 1 dose of HepB after which anti-HBs is tested*) using standard dose (SR, M)
21881
or high dose (40 μg)* (WR, L)
21881
for children and high dose for adolescents* and adults (SR, L)
21881
should be administered.
83. Administer 3 doses of IPV starting 6-12 months after HSCT. (SR, M)
21881
84. Consider administration of 3 doses of HPV starting at 6-12 months after HSCT for female patients ages 11-26 years and HPV4 in males ages 11-26 years. (WR, VL)
21881
85. Do not administer live vaccines to HSCT patients with active GVHD or ongoing immunosuppression. (SR, L)
21881
86. Administer a 2-dose series of MMR to measles-seronegative adolescents and adults (SR, L)
21881
and to measles-seronegative children (SR, M)
21881
starting 24 months after HSCT in patients with neither chronic GVHD nor ongoing immunosuppression and 8-11 months (or earlier if in a measles outbreak situation) after the last dose of immune globulin intravenous (IGIV).
87. Administer a 2-dose series of VAR starting 24 months after HSCT to varicella-seronegative patients with neither GVHD nor ongoing immunosuppression and 8-11 months after the last dose of IGIV. (SR, L)
21881

Table 4. Vaccinations Prior to or After Allogeneic or Autologous HSCT

H. influenzae type b conjugate

Pre-HSCT
U: (SR, M)
21881
Post-HSCT
R: 3 doses (SR, M)
at 6 mo post-tx
21881

Hepatitis A

Pre-HSCT
U: (SR, VL)
21881
Post-HSCT
R: 2 doses (WR, L)
at ≥6 mo post-tx
21881

Hepatitis B

Pre-HSCT
U: (SR, L)
21881
Post-HSCT
R: 3 doses (SR, M)
at 6–12 mo post-tx
21881

DTaP, DT, Td, Tdap

Pre-HSCT
U: (SR, L)
21881
Post-HSCT
R: age <7 y: DTaP 3 doses (SR, L)
at ≥6 mo posttx
21881
R: age ≥7 y: DTaP* 3 doses (WR, VL)
at ≥6 mo post-tx
21881
OR 1 dose Tdap, followed by either 2 doses DT* or 2 doses Td (DTaP) (WR, M)
21881
DT, Td (WR, L)
21881

HPV

Pre-HSCT
U: age 11-26 y (SR, VL)
21881
Post-HSCT
U: 3 doses at ≥6 mo post-tx (WR, VL)
21881

Influenza, inactivated

Pre-HSCT
U: (SR, L)
21881
Post-HSCT
R: ≥4 mo post-tx (SR, VL)
if community outbreak;
21881
otherwise ≥6 mo post-tx (SR, M)
21881

Influenza, live attenuated

Pre-HSCT
X: (WR, VL)
21881
Post-HSCT
X: (WR, VL)
21881

MMR, live

Pre-HSCT
U:a (SR, VL)
21881
Post-HSCT
X:b (SR, L)
21881

MMRV, live

Pre-HSCT
U:a (WR, VL)
21881
Post-HSCT
X: (SR, VL)
21881

Meningococcal conjugate

Pre-HSCT
U: (SR, VL)
21881
Post-HSCT
R: age 11-18 y: 2 doses (SR, L)
at 6-12 mo post-tx
21881

Pneumococcal conjugate (PCV13)

Pre-HSCT
R:c (SR, L)
21881
Post-HSCT
R: 3 doses (SR, L)
at 3-6 mo posttx
21881

Pneumococcal polysaccharide (PPSV23)

Pre-HSCT
R:c (SR, VL)
21881
Post-HSCT
R: ≥12 mo post-tx if no GVHD (SR, L)
21881

Poliovirus, inactivated

Pre-HSCT
U: (SR, VL)
21881
Post-HSCT
R: 3 doses (SR, M)
at ≥3 mo post-tx
21881

Rotavirus, live

Pre-HSCT
X: (WR, VL)
21881
Post-HSCT
X: (WR, VL)
21881

Varicella, live

Pre-HSCT
U:a (SR, L)
21881
Post-HSCT
X:d (SR, L)
21881

Zoster, live

Pre-HSCT
R:a,e age 50–59 y* (WR, VL)
21881
U:a age ≥60 y (SR, L)
21881
Post-HSCT
X: age 50–59 y* (SR, L)
21881
X: age ≥60 y (SR, L)
21881
R, recommended—administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection posttx, posttransplant
U, usual—administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories
X, contraindicated.
Footnotes to Table 4
a These live vaccines should not be administered unless the vaccine is otherwise indicated based on the annually updated CDC recommendations AND the patient is not immunosuppressed AND there will be an interval of ≥4 weeks prior to transplant. (, )
21881
b Administer to adolescents and adults (SR, L)
21881
and to children (SR, M)
21881
if measles-seronegative, the timing is ≥24 months after transplant, no GVHD is present, and the patient is not receiving immunosuppressive medication. Two doses should be administered.
c If not previously administered.
d Administer if varicella-seronegative, the timing is ≥24 months after transplant, no GVHD is present, and the patient is not receiving immunosuppressive medication. Two doses should be administered. (SR, L)
21881
e Consider if the patient is not severely immunosuppressed and the patient is varicella-immune as defined by documentation of age-appropriate varicella vaccination, serologic evidence of immunity, documentation of varicella or zoster infection, or birth in the United States before 1980 and there will be an interval of ≥4 weeks prior to transplant.

* This recommendation deviates from CDC ACIP recommendations.

Solid Organ Transplant (See Table 5)

Donors and Patients Before Transplantation

88. Living donors should be current with vaccines based on age, vaccination history, and exposure history according to the CDC annual schedule, (SR, H)
21881
but MMR, MMRV, VAR, and ZOS administration should be avoided within 4 weeks of organ donation. (WR, VL)
21881
Vaccination of donors solely for the recipient’s benefit is generally not recommended. (WR, L)
21881
89. Adults and children with chronic or end-stage kidney, liver, heart, or lung disease including SOT candidates should receive all age-, exposure history–, and immune status–appropriate vaccines based on the CDC annual schedule for immunocompetent persons. (SR, M)
21881
90. The following persons should receive PCV13 as in recommendations 27a-c: adults who are SOT candidates or have end-stage kidney disease as well as pediatric patients who are SOT candidates; those who are <6 years of age and have end-stage kidney, heart, or lung disease; and those who are 6-18 years of age and have end-stage kidney disease. (SR, VL)
21881
91. Adults and children age ≥2 years old who are SOT candidates or have end-stage kidney disease should receive PPSV23 if they have not received a dose within 5 years and have not received 2 lifetime doses. (SR, M)
21881
Patients with end-stage kidney disease should receive 2 lifetime doses 5 years apart. (SR, L)
21881
Adults and children ≥2 years of age with end-stage heart or lung disease as well as adults with chronic liver disease including cirrhosis should receive a dose of PPSV23 if they never have received a dose. (SR, L)
21881
When both PCV13 and PPSV23 are indicated, PCV13 should be completed 8 weeks prior to PPSV23. (SR, M)
21881
92. anti-HBs–negative SOT candidates should receive a HepB series, (SR, M)
21881
and if on hemodialysis and age ≥20 years they should receive a high-dose (40 µg) HepB series. (SR, M)
21881
If a postvaccination anti-HBs concentration of ≥10 mIU/mL is not attained, a second 3-dose series of HepB (SR, L)
21881
(Alternative: 1 dose of HepB after which anti-HBs is tested*) should be administered using the standard dose (SR, M)
21881
or high dose* for children (WR, L)
21881
and the high dose for adolescents* and adults. (SR, L)
21881
Hepatitis A–unvaccinated, undervaccinated, or seronegative SOT candidates (particularly liver transplant candidates) ages 12–23 months (SR, M)
21881
and those ≥2 years. (SR, M)
should receive a HepA series.
21881
93. Combined HepA-HepB vaccine can be used for SOT candidates ≥12 years of age* in whom both vaccines are indicated. (SR, M)
21881
94. HPV series should be administered to SOT candidates ages 11-26 years. (SR, )

(SR-L to M)

21881
95. SOT candidates 6-11 months of age can receive MMR if they are not receiving immunosuppression and transplantation is not anticipated within 4 weeks. (WR, VL)
21881
If transplantation is delayed (and the child is not receiving immunosuppression), MMR should be repeated at 12 months of age. (SR, M)
21881
96. VAR should be administered to SOT candidates without evidence of varicella immunity (as defined in recommendation 16) if they are not receiving immunosuppression and transplantation is not anticipated within 4 weeks. (SR, M)
21881
VAR can be administered to varicella-naive SOT candidates 6-11 months of age who are not immunosuppressed provided the timing is ≥4 weeks prior to transplant.* (WR, VL)
21881
Optimally, 2 doses should be administered ≥3 months apart. (SR, L)
21881
97. SOT candidates age ≥60 years (SR, M)
21881
and varicella-positive (as defined in recommendation 22) candidates ages 50-59 years.* (WR, L)
21881
who are not severely immunocompromised should receive ZOS if transplantation is not anticipated within 4 weeks.

SOT Recipients

98. Vaccination should be withheld from SOT recipients during intensified immunosuppression including the first 2-month post-transplant period because of the likelihood of inadequate response, (SR, L)
21881
except that IIV can be administered ≥1 month after transplant during a community influenza outbreak. (WR, VL)
21881
99. Standard age-appropriate inactivated vaccine series should be administered 2-6 months after SOT based on the CDC annual schedule, (SR, )

(SR-L to M)

21881
including IIV. (SR, M)
(Table 5)
21881
100. PCV13 should be administered starting 2-6 months after SOT if not administered before SOT, with timing based on the degree of immunosuppression of the individual patient, as described in recommendations 27a-c (Table 5). (SR, )
(SR-VL to M)
21881
101. For SOT patients ≥2 years of age, 1 dose of PPSV23 should be administered starting 2-6 months after SOT with timing based on the degree of immunosuppression of the individual patient, and ≥8 weeks after indicated doses of PCV13, if not given within 5 years and if patient has received no more than 1 previous lifetime dose. (SR, M)
21881
102. HepB should be considered for chronic hepatitis B-infected recipients starting 2-6 months after liver transplant in an attempt to eliminate the lifelong requirement for hepatitis B immune globulin.* (WR, L)
21881
103. MMR and VAR should generally not be administered to SOT recipients because of insufficient safety and effectiveness data, (SR, L)
21881
except for VAR in children without evidence of immunity (as defined in recommendation 15) who are renal or liver transplant recipients and are receiving minimal or no immunosuppression and have no recent graft rejection.* (WR, M)
21881
104. Vaccination should not be withheld because of concern about transplant organ rejection. (SR, M)
21881

Table 5. Vaccinations Prior to or After Solid Organ Transplant

H. influenzae type b conjugate

Pretransplant
U: (SR, M)
21881
Starting 2–6 Months Posttransplant
U: (SR, M)
21881

Hepatitis A

Pretransplant
U: age 12-23 mo (SR, M)
21881
R: age ≥2 y (SR, M)
21881
Starting 2–6 Months Posttransplant
R: if not completed pretransplant (SR, M)
21881

Hepatitis B

Pretransplant
U: age 1-18 y (SR, M)
21881
R: age ≥18 y (SR, M)
21881
Starting 2–6 Months Posttransplant
R: if not completed pretransplanta (SR, M)
21881

DTaP, Tdap

Pretransplant
U: (SR, M)
21881
Starting 2–6 Months Posttransplant
U: if not completed pretransplant (SR, M)
21881

HPV

Pretransplant
U: females age 11-26 y (SR, M)
21881
Starting 2–6 Months Posttransplant
U: females age 11-26 y (SR, M)
21881
U: males age 11-26 y (SR, L)
21881

Influenza, inactivated

Pretransplant
U: (SR, M)
21881
Starting 2–6 Months Posttransplant
U:b (SR, M)
21881

Influenza, live attenuated

Pretransplant
X: (WR, L)
21881
Starting 2–6 Months Posttransplant
X: (WR, L)
21881

MMR, live

Pretransplant
R:c age 6-11 mo (WR, VL)
21881
U:d age ≥12 mo (SR, M)
21881
Starting 2–6 Months Posttransplant
X: (SR, L)
21881

MMRV, live

Pretransplant
U:d (SR, M)
21881
Starting 2–6 Months Posttransplant
X: (SR, L)
21881

Meningococcal conjugate

Pretransplant
U: (SR, M)
21881
Starting 2–6 Months Posttransplant
U: (SR, M)
21881

Pneumococcal conjugate (PCV13)

Pretransplant
U: age <5 y (SR, M)
21881
R: age ≥6 ye (SR, VL)
21881
Starting 2–6 Months Posttransplant
U: age 2-5 y (SR, M)
21881
R: age ≥6 y, if not administered pretransplante (SR, VL)
21881

Pneumococcal polysaccharide (PPSV23)

Pretransplant
R: age ≥2 y (SR, M)
21881
Starting 2–6 Months Posttransplant
R: age ≥2 y, if not administered pretransplant (SR, M)
21881

Poliovirus, inactivated

Pretransplant
U: (SR, M)
21881
Starting 2–6 Months Posttransplant
U: (SR, M)
21881

Rotavirus, live

Pretransplant
U:c (SR, M)
21881
Starting 2–6 Months Posttransplant
X: (SR, L)
21881

Varicella, live

Pretransplant
R:f age 6-11 mo (WR, VL)
21881
U:d (SR, L)
21881
Starting 2–6 Months Posttransplant
X:g (SR, L)
21881

Zoster, live

Pretransplant
R:h age 50-59 y (WR, L)
21881
U:i age ≥60 y (SR, M)
21881
Starting 2–6 Months Posttransplant
X: (SR, L)
21881
R, recommended—administer if not previously administered or not current; such patients may be at increased risk for this vaccine-preventable infection
U, usual—administer if patient not current with recommendations for dose(s) of vaccine for immunocompetent persons in risk and age categories
X, contraindicated.
a Consider hepatitis B vaccine for hepatitis B-infected liver transplant patients. (WR, L)
21881
b IIV may be administered to SOT recipients despite intensive immunosuppression (eg, during the immediate posttransplant period), particularly in an outbreak situation. (WR, L)
21881
c Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant.
d Administer only if patient is nonimmune, not severely immunosuppressed, and the timing is ≥4 weeks prior to transplant.
e For patients ≥19 years who have previously received PPSV23, PCV13 should be administered after an interval of ≥1 year after the last PPSV23 dose. (WR, L)
21881
f Administer only if patient is not immunosuppressed and the timing is ≥4 weeks prior to transplant.*
g Selected seronegative patients with a renal or liver transplant have been safely vaccinated.*
h Administer only if patient is not severely immunosuppressed, the timing is ≥4 weeks prior to transplant, and the patient is varicella-immune as defined by documentation of age-appropriate varicella vaccination, serologic evidence of immunity, documentation of varicella or zoster infection, or birth in the United States before 1980. *
i Administer only if patient is not severely immunosuppressed and the timing is ≥4 weeks prior to transplant.

* These recommendations deviate from CDC ACIP recommendations.

Chronic Inflammatory Disease Patients Taking Immunosupporessants (See Table 6)

105. Inactivated vaccines, including IIV, should be administered to patients with chronic inflammatory illness treated with (SR, )

(SR-L to M)

21881
or about to be treated with immunosuppressive agents. (SR, M)
21881
as for immunocompetent persons based on the CDC annual schedule.
106. PCV13 should be administered to adults and children with a chronic inflammatory illness treated with immunosuppression as described in the standard schedule for children and in recommendations 27a-c and Table 6. (SR, )
(SR-VL to M)
21881
107. PPSV23 should be administered to patients ≥2 years of age with chronic inflammatory illness with planned initiation of immunosuppression, (SR, L)
21881
low-level immunosuppression, (SR, L)
21881
and high-level immunosuppression. (SR, VL)
21881
Patients should receive PPSV23 ≥8 weeks after PCV13 and should receive a second dose of PPSV23 5 years later. (SR, L)
21881
108. VAR should be administered to patients with chronic inflammatory disease without evidence of varicella immunity (defined in recommendation 15) (SR, M)
21881
≥4 weeks prior to initiation of immunosuppression, (SR, L)
21881
if treatment initiation can be safely delayed.
109. VAR should be considered for patients without evidence of varicella immunity (defined in recommendation 15) treated for chronic inflammatory disease with long-term, low-level immunosuppression.* (WR, VL)
21881
110. ZOS should be administered to patients with a chronic inflammatory disorder who are ≥60 years of age prior to initiation of immunosuppression (SR, L)
21881
or while being treated with low-dose immunosuppression, (SR, VL)
21881
and to those who are 50-59 years of age and varicella-positive prior to initiation of immunosuppression* (WR, L)
21881
or while being treated with low-dose immunosuppression.* (WR, VL)
21881
111. Other live vaccines should NOT be administered to patients with chronic inflammatory diseases who are receiving maintenance immunosuppression: LAIV, (WR, VL)
21881
MMR in patients receiving low-level (WR, VL)
21881
or high-level immunosuppression, (WR, VL)
21881
and MMRV in patients receiving low-level (WR, VL)
21881
or high-level immunosuppression. (SR, VL)
21881
112. Otherwise recommended vaccines, including IIV and HepB, should not be withheld because of concerns about exacerbation of chronic immune-mediated or inflammatory illness. (SR, M)
21881

Table 6. Vaccination of Persons With Chronic Inflammatory Diseases on Immunosuppressive Medications

H. influenzae type b conjugate

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, L)
21881
High-Level Immunosuppressiona
U: (SR, L)
21881

Hepatitis A

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, L)
21881
High-Level Immunosuppressiona
U: (SR, L)
21881

Hepatitis B

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, L)
21881
High-Level Immunosuppressiona
U: (SR, L)
21881

DTaP, Td, Tdap

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, L)
21881
High-Level Immunosuppressiona
U: (SR, L)
21881

HPV

Planned Immunosuppression
U: age 11-26 y (SR, M)
21881
Low-Level Immunosuppressiona
U: age 11-26 y (SR, L)
21881
High-Level Immunosuppressiona
U: age 11-26 y (SR, VL)
21881

Influenza, inactivated

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, M)
21881
High-Level Immunosuppressiona
U: (SR, M)
21881

Influenza, live attenuated

Planned Immunosuppression
X: (WR, VL)
21881
Low-Level Immunosuppressiona
X: (WR, VL)
21881
High-Level Immunosuppressiona
X: (WR, VL)
21881

MMR, live

Planned Immunosuppression
U:b (SR, M)
21881
Low-Level Immunosuppressiona
X: (WR, VL)
21881
High-Level Immunosuppressiona
X: (WR, VL)
21881

MMRV, live

Planned Immunosuppression
U:b (SR, L)
21881
Low-Level Immunosuppressiona
X: (WR, VL)
21881
High-Level Immunosuppressiona
X: (SR, VL)
21881

Meningococcal conjugate

Planned Immunosuppression
U: (SR, M)
21881
Low-Level Immunosuppressiona
U: (SR, M)
21881
High-Level Immunosuppressiona
U: (SR, L)
21881

Pneumococcal conjugate (PCV13)

Planned Immunosuppression
R:c (SR, M)
21881
Low-Level Immunosuppressiona
U: age <6 y (SR, L)
21881
R: age ≥6 yc (SR, VL)
21881
High-Level Immunosuppressiona
U: age <6 y (SR, L)
21881
R: age ≥6 yc (SR, VL)
21881

Pneumococcal polysaccharide (PPSV23)

Planned Immunosuppression
R: age ≥2 y (SR, L)
21881
Low-Level Immunosuppressiona
R: age ≥2 y (SR, L)
21881
High-Level Immunosuppressiona
R: age ≥2 y (SR, VL)
21881

Poliovirus, inactivated